A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Vulvovaginal candidiasis
- Focus Registrational; Therapeutic Use
- Sponsors SCYNEXIS
- 03 Jan 2019 Status changed from not yet recruiting to recruiting.
- 08 Nov 2018 Planned number of patients changed from 400 to 366.
- 07 Nov 2018 Status changed from planning to not yet recruiting.